News & Announcements
Gliknik locks up licenses to develop cancer drugs
September 19, 2008
Baltimore Business Journal - by Sue Schultz Staff
Gliknik, a Baltimore biotechnology firm, has secured the rights to develop two cancer vaccines.
The biotech firm, creating drugs for autoimmune diseases and cancer, reached an agreement with the University of Maryland, Baltimore and the Mayo Clinic for the drugs, which are now in clinical trials for head and neck cancer.
“We are encouraged by the novelty and clinical trial results to date of these drug candidates and pleased to become a clinical stage development company early in the progress of our company’s growth,” said Gliknik CEO Dr. David Block in a statement.
The company, founded in 2007, was spun out of work by Dr. Scott Strome, professor and chairman of the Department of Otorhinolarynogology-Head & Neck Surgery at the University of Maryland School of Medicine in Baltimore.
Block served as the former chief operating officer of Celera Genomics. He also launched and ran Ruxton Pharmaceuticals, a local venture capital-backed company.
Gliknik moved into the UM BioPark in March.